Archives of Clinical Infectious Diseases

Published by: Kowsar

First Report of the Prevalence of Human T-Lymphotropic Virus Type 1 (HTLV-1) for Hemodialysis Patients in Tehran

Reza Yazdani 1 , Maryam Dadmanesh 2 and Khodayar Ghorban 3 , *
Authors Information
1 Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Infectious Diseases,School of Medicine, AJA University of Medical Sciences, Tehran, Iran
3 Department of Immunology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
Article information
  • Archives of Clinical Infectious Diseases: August 2018, 13 (4); e65512
  • Published Online: August 15, 2018
  • Article Type: Research Article
  • Received: March 27, 2017
  • Revised: December 24, 2017
  • Accepted: January 14, 2018
  • DOI: 10.5812/archcid.65512

To Cite: Yazdani R, Dadmanesh M, Ghorban K. First Report of the Prevalence of Human T-Lymphotropic Virus Type 1 (HTLV-1) for Hemodialysis Patients in Tehran, Arch Clin Infect Dis. 2018 ; 13(4):e65512. doi: 10.5812/archcid.65512.

Abstract
Copyright © 2018, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnote
References
  • 1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. P Natl A Sci. 1980;77(12):7415-9. doi: 10.1073/pnas.77.12.7415.
  • 2. Kalyanaraman VS, Sarngadharan MG, Poiesz B, Ruscetti FW, Gallo RC. Immunological properties of a type C retrovirus isolated from cultured human T-lymphoma cells and comparison to other mammalian retroviruses. J Virol. 1981;38(3):906-15. [PubMed: 6264163]. [PubMed Central: PMC171228].
  • 3. Gessain A, Vernant J, Maurs L, Barin F, Gout O, Calender A, et al. Antibodies to human T-lymphotropic virus type-i in patients with tropical spastic paraparesis. The Lancet. 1985;326(8452):407-10. doi: 10.1016/s0140-6736(85)92734-5.
  • 4. Blattner WA, Takatsuki K, Gallo RC. Human T-cell leukemia-lymphoma virus and adult T-cell leukemia. JAMA. 1983;250(8):1074-80. [PubMed: 6308291].
  • 5. Monplaisir N, Neisson-Vernant C, Bouillot M, Duc-Dodon M, Ugarte E, Valette I, et al. HTLV-I maternal transmission in Martinique, using serology and polymerase chain reaction. AIDS Res Hum Retroviruses. 1993;9(9):869-74. doi: 10.1089/aid.1993.9.869. [PubMed: 7903044].
  • 6. Murphy EL, Figueroa JP, Gibbs WN, Brathwaite A, Holding-Cobham M, Waters D, et al. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med. 1989;111(7):555-60. [PubMed: 2789009].
  • 7. Soriano V, Pauplana M, Ribera A, Tor J, Foz M. [Antibodies against HTLV-1 in patients undergoing multiple transfusions]. Rev Clin Esp. 1989;185(9):448-50. [PubMed: 2623278].
  • 8. de Thé G, Kazanji M. An HTLV-I/II vaccine: from animal models to clinical trials? J Acq Immun Def Synd. 1996;13:S191-8. doi: 10.1097/00042560-199600001-00029.
  • 9. Morofuji-Hirata M, Kajiyama W, Nakashima K, Noguchi A, Hayashi J, Kashiwagi S. Prevalence of antibody to human T-cell lymphotropic virus type I in Okinawa, Japan, after an interval of 9 years. Am J Epidemiol. 1993;137(1):43-8. [PubMed: 8434571].
  • 10. Blattner WA, Kalyanaraman VS, Robert-Guroff M, Lister TA, Galton DA, Sarin PS, et al. The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. Int J Cancer. 1982;30(3):257-64. [PubMed: 6290401].
  • 11. Reeves WC, Saxinger C, Brenes MM, Quiroz E, Clark JW, Hoh MW, et al. Human T-cell lymphotropic virus type I (HTLV-I) seroepidemiology and risk factors in metropolitan Panama. Am J Epidemiol. 1988;127(3):532-9. [PubMed: 2893539].
  • 12. Maloney EM, Ramirez H, Levin A, Blattner WA. A survey of the human T-cell lymphotropic virus type I (HTLV-I) in south-western Colombia. Int J Cancer. 1989;44(3):419-23. [PubMed: 2777408].
  • 13. Saxinger W, Blattner WA, Levine PH, Clark J, Biggar R, Hoh M, et al. Human T-cell leukemia virus (HTLV-I) antibodies in Africa. Science. 1984;225(4669):1473-6. [PubMed: 6089348].
  • 14. Meytes D, Schochat B, Lee H, Nadel G, Sidi Y, Cerney M, et al. Serological and molecular survey for HTLV-I infection in a high-risk Middle Eastern group. Lancet. 1990;336(8730):1533-5. [PubMed: 1979367].
  • 15. Tabei SZ, Rajabian R, Shirde H. Adult T-cell leukemia/lymphoma in the northestern province of Iran. Iran J Med Sci. 1986;13(2-4):2-4.
  • 16. Farid R, Poryamoth N, Godarzi A, Rafatpanah H, Amin H, Gessain A. Afamilial seroepidemiological survey of HTLV-1 in Mashhad, Northeastern Iran suggested an important mother to childtransmision. J AIDS Hum Retrovirol. 1995;10:209-12.
  • 17. Farid R, Etemadi MM, Baradaran H, Shirdel A, Ahkami N, Safai S. Screening sera from the adult populations of Mashhad and Gonbad for anti bodies to HTLV-1. Med J Islamic Republic Iran (MJIRI). 1992;6(2):85-6.
  • 18. Khameneh ZR, Baradaran M, Sepehrvand N. Survey of the seroprovalence of HTLV I/II in hemodialysis patients and blood donors in Urmia. Saudi J Kidney Dis Transpl. 2008;19(5):838-41. [PubMed: 18711311].
  • 19. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24(39):6058-68. doi: 10.1038/sj.onc.1208968. [PubMed: 16155612].
  • 20. Courouce AM, Pillonel J, Saura C. Screening of blood donations for HTLV-I/II. Transfus Med Rev. 1999;13(4):267-74. [PubMed: 10553270].
  • 21. Biglione MM, Astarloa L, Salomon HE; Referent HTLV-I/II Argentina Group. High prevalence of HTLV-I and HTLV-II among blood donors in Argentina: a South American health concern. AIDS Res Hum Retroviruses. 2005;21(1):1-4. doi: 10.1089/aid.2005.21.1. [PubMed: 15665638].
  • 22. Al-Mufti S, Voevodin A, Ahmed S, Al Hamdan S, Al-Basheer AA. Seroprevalence of human T-cell leukemia/lymphoma virus type i and type II (HTLV-I/HTLV-II) infection among volunteer blood donors in Kuwait. Med Prin Pract. 1999;8(1):45-50. doi: 10.1159/000026068.
  • 23. Fawaz NA, Tamim H, Almawi WY. Low prevalence of antibodies to human T-lymphotropic virus-I/II among blood donors in eastern Saudi Arabia. Am J Infect Control. 2005;33(3):189-91. doi: 10.1016/j.ajic.2004.08.006. [PubMed: 15798675].
  • 24. Azarpazhooh MR, Hasanpour K, Ghanbari M, Rezaee SA, Mashkani B, Hedayati-Moghaddam MR, et al. Human T-lymphotropic virus type 1 prevalence in northeastern Iran, Sabzevar: an epidemiologic-based study and phylogenetic analysis. AIDS Res Hum Retroviruses. 2012;28(9):1095-101. doi: 10.1089/AID.2011.0248. [PubMed: 22229796].
  • 25. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol. 2011;52(3):172-6. doi: 10.1016/j.jcv.2011.07.004. [PubMed: 21840754].
  • 26. Hedayati-Moghaddam MR, Fathimoghadam F, Eftekharzadeh Mashhadi I, Soghandi L, Bidkhori HR. Epidemiology of HTLV-1 in Neyshabour, Northeast of Iran. Iran Red Crescent Med J. 2011;13(6):424-7. [PubMed: 22737506]. [PubMed Central: PMC3371930].
  • 27. Dadmanesh M, Hosseinzadeh M, Keyvani H, Ghorban K, Rahimi M, Hosseinzadeh M, et al. Evaluation of prevalence and risk factors of hepatitis g virus infection among hemodialysis patients referred to Iranian army hospitals in tehran during 2012-2013. Hepat Mon. 2015;15(1). e18322. doi: 10.5812/hepatmon.18322. [PubMed: 25741370]. [PubMed Central: PMC4330714].
  • 28. Dadmanesh M, Ranjbar MM, Alavian SM, Ghorban K. Sequencing and phylogenetic study of partial NS3 gene of Iranian GB virus C/hepatitis G virus (HGV) originated from hemodialysis patients in Tehran. Hepat Mon. 2015;15(3). e24173. doi: 10.5812/hepatmon.24173. [PubMed: 25838830]. [PubMed Central: PMC4379489].
  • 29. Safai B, Huang JL, Boeri E, Farid R, Raafat J, Schutzer P, et al. Prevalence of HTLV type I infection in Iran: a serological and genetic study. AIDS Res Hum Retroviruses. 1996;12(12):1185-90. doi: 10.1089/aid.1996.12.1185. [PubMed: 8844023].
  • 30. Salehi M, Shokouhi Mostafavi SK, Ghasemian A, Gholami M, Kazemi-Vardanjani A, Rahimi MK. Seroepidemiology of HTLV-1 and HTLV-2 Infection in Neyshabur City, North-Eastern Iran, during 2010-2014. Iran Biomed J. 2017;21(1):57-60. [PubMed: 26899860]. [PubMed Central: PMC5141255].
  • 31. Ghaffari J, Naghshvar F, Nazari Z, Farid R, Torabizadeh J, Madani F. Seroprevalence of human T-cell lymphotropic virus type 1 infection (HTLV1) in different patients in the north of Iran. Afr J Biotechnol. 2011;10(52):10752-5. doi: 10.5897/ajb11.177.
  • 32. Kalavi KH, Moradi A, Ahmadi AR, Sarikhani AJ, Bazoori M, Kyaee M. Prevalence of HTLV-1 infection in Golestan Province, Iran. Med Lab J. 2008;2(1):0.
  • 33. Ghaderi A, Habib-Agahi M. High prevalence of anti-HCV and HTLV-1 antibodies in thalassemia major patients of southern Iran. Irn J Med Sci. 1996;21(1).
  • 34. Pourkarim MR, HAJIANI GR, KHAMISIPOUR GR, Ardeshirdavani N, Tahmasebi R. Seroepidemiological investigation of HTLV I, II infection among Busherian multi-transfused patients in 2003. Scientific J Iran Blood. 2005;2(4).
  • 35. Karimi A, Nafici M, Imani R. Comparison of human T-cell leukemia virus type-1 (HTLV-1) seroprevalence in high risk patients (thalassemia and hemodialysis) and healthy individuals from Charmahal-Bakhtiari province, Iran. Kuwait Med J. 2007;39(3):259.
  • 36. Moradi A, Ahmadi AR, Bakhshandeh-Nosrat S, Sanee-Moghaddam E, Saeedi M. Survey of HTLV-1 antibody among thalassemic patients in Gorgan. Med Lab J. 2007;1(1):0.
  • 37. Anaraki Mohammadi GH, Sadeghipour AR, Vossough P, Nour Mohammadi I, Mirnateghi AM. [Assessment of the prevalence of human T-lymphotropic virus type 1 among thalassemic patients with frequent blood transfusion in Tehran in 2003]. Razi J Med Sci. 2005;12(47):19-24. Persian.
  • 38. Hedayati-Moghaddam MR, Amini AR. HTLV-1 infection as a serious health issue among Iranian multi-transfused patients: evidence from a systematic review and meta-analysis. Iran J Blood Cancer. 2015;7(2):85-94.
  • 39. Bidkhori HR, Hedayati-Moghaddam MR, Fathi-Moghaddam F, Soghandi L, Bakhtiari H, Rezaie A. High prevalence of HTLV-1 infection among hemodialysis patients in Neyshabour, Northeast of Iran. Iran J Allergy Asthma Immunology. 2013;12(Suppl 9):38.
  • 40. Ardalan N, Abdi M, Rahimian Zarif B, Amini A, Meamari F, Haydari E, et al. Prevalence of human T-lymphotropic virus types I&II among high risk groups in Sanandaj in 2010. Scientific J Kurdistan U Med Sci. 2013;18(2):51-7.
  • 41. Ghaffari J, Ebrahimi M, Makhlough A, Mohammadjafari H, Nazari Z. Seroepidemiology of human T-cell lymphotropic virus 1 infection in hemodialysis patients: should we be concerned about it? Iran J Kidney Dis. 2013;7(3):187-90. [PubMed: 23689148].
  • 42. Santos RF, Conceicao GC, Martins MS, Kraychete A, Penalva MA, Carvalho EM, et al. Prevalence and risk factors for Human T-Lymphotropic Virus Type 1 (HTLV-1) among maintenance hemodialysis patients. BMC Nephrol. 2017;18(1):64. doi: 10.1186/s12882-017-0484-y. [PubMed: 28202003]. [PubMed Central: PMC5312583].
  • 43. Hekmat R, Gholami F, Ahmadnia H, Ahmadi M, Hassannia T. Serum human T-lymphotropic virus 1 proviral load in patients on hemodialysis. Iran J Kidney Dis. 2013;7(2):124-8. [PubMed: 23485536].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments